Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Current Leases (2019 - 2025)

Viking Therapeutics (VKTX) has disclosed Current Leases for 7 consecutive years, with $137000.0 as the latest value for Q4 2025.

  • For Q4 2025, Current Leases fell 71.98% year-over-year to $137000.0; the TTM value through Dec 2025 reached $137000.0, down 71.98%, while the annual FY2025 figure was $137000.0, 71.98% down from the prior year.
  • Current Leases hit $137000.0 in Q4 2025 for Viking Therapeutics, down from $437000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $498000.0 in Q1 2025 and bottomed at $29000.0 in Q4 2021.
  • Average Current Leases over 5 years is $302500.0, with a median of $311500.0 recorded in 2023.
  • Year-over-year, Current Leases crashed 91.21% in 2021 and then surged 948.28% in 2022.
  • Viking Therapeutics' Current Leases stood at $29000.0 in 2021, then soared by 948.28% to $304000.0 in 2022, then increased by 6.58% to $324000.0 in 2023, then soared by 50.93% to $489000.0 in 2024, then crashed by 71.98% to $137000.0 in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $137000.0, $437000.0, and $468000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.